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Introduction 1 
 2 
Asthma is a heterogeneous chronic inflammatory disease of global importance1, 3 
which places a significant burden both on individual patients and on health care 4 
services, where many patients remain inadequately treated2, 3 with an ongoing 5 
attendant mortality4.  The concept of achieving ‘total asthma control’5 is 6 
important for reducing the future risk of exacerbations6-8.  It is therefore 7 
imperative that we have robust procedures for accurate diagnosis, measurement 8 
of severity, prediction of future risk, along with appropriate personalised 9 
treatments to achieve this goal.  Nevertheless, present guidelines for the 10 
identification and treatment of asthma merely include symptoms and lung 11 
function measurements5, 9.  The Royal College of Physicians’ recent National 12 
Review of Asthma Deaths report4 found that only 39% of patients who died were 13 
actually labelled as having ‘severe’ asthma according to current guidelines, with 14 
the remainder therefore labelled as ‘mild’ or ‘moderate’, suggesting we may not 15 
be accurately identifying those at greatest risk. 16 
 17 
Measurement of inflammatory outcomes has improved our understanding of 18 
asthma, evolving personalised treatment.  Studies have shown that titrating 19 
steroid therapy against inflammation may improve outcomes such as 20 
exacerbation rates10-12. For example in one primary care based study titrating 21 
inhaled corticosteroid dose against mannitol challenge verses a reference 22 
strategy, resulted in a 27% significant reduction in mild exacerbations but no 23 
difference in severe exacerbations11.  Similar findings were observed in another 24 
study using methacholine challenge13. Green et al. demonstrated this by titrating 25 
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steroid treatment against sputum eosinophil counts, resulting in significantly 26 
fewer severe exacerbations compared to standard guideline driven treatment10.  27 
It is interesting that this was achieved with no difference in overall mean dosage 28 
of ICS between the two groups, suggesting that for the individual, any steroid 29 
titration was performed at the right time for them when their levels of 30 
inflammation were greater.  However, other studies have suggested a more 31 
muted response to inflammatory steroid titration in unselected asthmatic 32 
patients14, 15. 33 
 34 
Price et al. demonstrated retrospectively, in a primary care cohort, that 35 
asthmatic patients with higher blood eosinophil counts fared worse in terms of 36 
experiencing more severe exacerbations and poorer asthma control16.  37 
Moreover, eosinophilic inflammation may be masked when using a long-acting 38 
beta-2 agonist (LABA) as a steroid-sparing agent17, 18.  Sputum and blood 39 
eosinophilia in asthma have both been separately shown to predict loss of 40 
asthma control and increased exacerbation rates6, 19, 20.  This is also true of 41 
fractional exhaled nitric oxide (FeNO) levels21 and airway hyper-responsiveness 42 
(AHR)6, the latter being largely driven by airway inflammation22. It is therefore 43 
logical that one might wish to control inflammation over and above simply 44 
controlling symptoms and lung function – much like controlling asymptomatic 45 
hypertension to prevent subsequent cardiovascular sequelae.  This is relevant 46 
given lung function and lack of symptoms may be deemed normal despite the 47 
possibility of an ongoing underlying inflammatory process23. 48 
 49 
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We performed a post-hoc pooled analysis of data from four previously published 50 
randomised controlled trials (RCTs) where inhaled corticosteroid (ICS) dose 51 
titration was used in a prospective manner.  Outcome measurements included 52 
symptoms, lung function, inflammation and AHR.  We then analysed the dose-53 
response relationship to ICS for these outcomes to identify where incremental 54 
ICS dosing provides the greatest impact, and thus likely to be most informative 55 
when titrating a given individual’s treatment to achieve optimal or total asthma 56 
control.  57 
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Methods 58 
 59 
Patients 60 
 61 
Male and female mild-moderate, non-smoking, persistent asthmatics aged 18-65 62 
years receiving ≤1000µg/day ICS, i.e. expressed as a reference dose of large 63 
particle beclomethasone dipropionate (BDP) equivalent dose, were recruited to 64 
each of four RCTs11, 24-26.  For example, large particle HFA-fluticasone 200ug or 65 
small particle HFA-beclomethasone 200ug would be equivalent to large particle 66 
HFA-BDP 400ug.  Their post-run-in baseline measurements are presented in 67 
Table 1.  Further detailed inclusion and exclusion criteria can be found in each of 68 
the reported trials. 69 
 70 
Study Design 71 
 72 
We performed a post-hoc analysis using data from 4 RCTs11, 24-26, each 73 
comprising a component where the effects of ICS dose ramp increments were 74 
examined on a variety of outcomes including: spirometry, FeNO, AHR including 75 
both indirect (mannitol) and direct (methacholine, histamine) challenges, 76 
asthma symptoms, serum eosinophilic cationic protein (ECP), and blood 77 
eosinophil count (Eos).  Briefly, one study used large particle hydrofluoroalkane 78 
(HFA)-fluticasone propionate (FP) using FeNO as the primary outcome24: with 79 
an ICS-free run-in, followed by either 200µg or 800ug BDP equivalent.  A second 80 
study titrated small particle HFA-ciclesonide against mannitol AHR versus 81 
titration using standard British Thoracic Society (BTS) guidelines11: patients 82 
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were selected from both arms of this study where there was an appropriate dose 83 
ramp (i.e. BDP equivalent 200-800µg/day).  A third study used methacholine 84 
AHR as the primary outcome comparing large particle (HFA) and 85 
chlorofluorocarbon (CFC) formulations of budesonide25: within the HFA arm 86 
there was an ICS free washout followed by 200µg/day or 800ug/day BDP 87 
equivalent.  The fourth study examined whether propranolol was useful as an 88 
ICS sparing agent26, with histamine AHR the primary outcome: the control arm 89 
was effectively a dose ramp between small particle HFA-beclomethasone at BDP 90 
equivalent doses of 200µg/day or 800ug/day. 91 
 92 
Measurements 93 
 94 
Extended detail of measurements can be found in each parent study.  Briefly, 95 
spirometry was measured using a SuperSpiro spirometer (Micro Medical Ltd.) 96 
according to American Thoracic Society (ATS) guidelines27.  Exhaled tidal nitric 97 
oxide was measured according to ATS recommendations28 using a NIOX analyser 98 
(NIOX® Nitric Oxide Monitoring System, Aerocrine AB) prior to other pulmonary 99 
function measures.  Mannitol challenge was performed as previously described29 100 
with a dry powder inhaler (Aridol; Pharmaxis Ltd) using cumulative dose 101 
increments up to 635 mg.  Histamine for bronchial challenge was dispensed via 102 
nebulized solution with doubling concentrations of histamine from 103 
0.3125mg/ml to 40mg/ml.  Methacholine challenge was performed using the 104 
five-breath dosimeter technique in accordance within ATS recommendations30. 105 
Peripheral blood eosinophils were measured using the Sysmex XE2100 106 
Hematology auto-analyser. Serum ECP was measured in duplicate using a 107 
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UniCAP system (Phadia) with a coefficient of variation of 3%.  For symptoms, 3 108 
studies11, 24, 26 included the mini-Asthma Quality of Life Questionnaire (AQLQ, 109 
symptom component), where a mean score of 7 indicates no symptoms, and <7 110 
indicates progressively worse symptoms.  In the fourth study25, the following 111 
rating scales were used: 0, no asthma symptoms; 1, mild symptoms (easily 112 
tolerable); 2, moderate symptoms (interferes with normal activities/sleep); and 113 
3, severe (prevents normal activities/ sleep).  The total asthma symptom score 114 
was a mean of both morning and evening symptom scores.  115 
 116 
Statistical Analysis 117 
 118 
All data were initially assessed for normality of distribution, with non-Gaussian 119 
distributions logarithmically transformed to enable parametric analyses.  For the 120 
primary analyses, examining for any change within a given outcome measure 121 
following an ICS dose ramp, arithmetic means of the difference within each ICS 122 
dose ramp were calculated for outcomes with the same parametric measure 123 
across all 4 studies.  Geometric mean fold differences were calculated for 124 
changes in outcomes that were either non-parametric, or with different 125 
measurements between the studies in order to standardize any changes (e.g. 126 
bronchial challenges).  Analyses of variance (ANOVA) with Bonferroni correction 127 
were also used to compare the differences between dose ramp responses, and 128 
each individual dose mean.  Multiple linear regression analyses, using both 129 
forward stepwise and non-hierarchical introduction of predictors, were also 130 
employed to examine for any confounding effects of biological covariates on the 131 
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main outcome measures.  Statistical significance for all comparisons was set at 132 
P<0.05.  Statistical analyses were performed using IBM SPSS version 22. 133 
 134 
Ethics 135 
 136 
The East of Scotland Research Ethics Service granted ethical approval for all 137 
studies (Refs: NFB/FB/192/0311, 09/S0501/5224, 11/ES/003126, 138 
08/S1402/1425). All patients provided written informed consent. The studies 139 
were registered at ClinicalTrials.gov: NCT0066799225, NCT0099565724, 140 
NCT0121657911, NCT0154463426. 141 
  142 
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Results 143 
 144 
We included 121 evaluable participants from the parent studies (Table 1).  145 
Ciclesonide patients were approximately 10 years older.  Patients had generally 146 
preserved pulmonary function, overall mean FEV1 85.1% predicted, and had 147 
mild symptoms.  FeNO was higher in the Fluticasone group due to the inclusion 148 
criteria of that study.  Despite the different bronchial challenges, their figures all 149 
indicated a moderate-severe degree of AHR.  Patients had been receiving similar 150 
ICS doses prior to study inclusion, mean 420µg/day BDP equivalent. 151 
 152 
For pulmonary function, there were small but statistically significant changes 153 
seen within the 0-200µg dose ramp for both FEV1 and FEF25-75 (Table 2, Figure 154 
1), with a 3.3% (95%CI 2.0,4.7) rise in FEV1 (P<0.0001), and 4.6% (95%CI 155 
2.4,6.9) rise in FEF25-75 (P<0.0001).  However, there was a plateau in response at 156 
200-800µg for both these measures.  There were also statistically significant 157 
within-group improvements for symptom scores (Figure 1) at all dose ramps, 158 
but with less improvement within the 200-800ug dose ramp: along with a 159 
significant difference (P=0.01) when comparing responses between 0-800µg vs. 160 
200-800µg, i.e. again indicating a plateau in response. 161 
 162 
For inflammation, significant improvements in FeNO were seen across all ICS 163 
dose ramps (Table 2, Figure 2a), with clear evidence of dose separation (Table 164 
2).  Improvements were more pronounced in the subgroup with baseline values 165 
of FeNO≥25ppb (Figure 2b), and significantly different compared to the 166 
subgroup with baseline values of FeNO<25ppb.  Serum ECP did not improve with 167 
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the low dose ramp 0-200µg (Table 2, Figure 2c), rather requiring the higher ICS 168 
dose to achieve significant within-group improvements between 0-800µg 169 
(P=0.002) and 200-800µg (P=0.0002); again the dose ramp responses were 170 
significantly different between 0-200µg and 200-800µg (P<0.05).  Finally there 171 
were significant within group improvements for blood Eos across all dose ramps 172 
(Table 2, Figure 2d), where Eos also continued to fall significantly as the ICS dose 173 
increased: 370cells/µL (95%CI 280,450) at 0µg, to 250cells/µL (95%CI 200,300) 174 
at 800µg, P=0.03. 175 
 176 
Significant within group changes were seen across all dose ramps for AHR 177 
(Figure 3a).  The greatest improvement was in the 0-800µg group at 1.35 178 
doubling dilutions (DD) (95%CI 1.06,1.63), P<0.0001, with further significant 179 
improvement in the 200-800µg group amounting to 0.7DD (95%CI 0.43,0.96), 180 
P<0.0001.  Significantly greater improvements were seen when AHR was 181 
separated into indirect (mannitol) versus direct challenges (histamine, 182 
methacholine), particularly at the lower dose ramp 0-200µg, 1.64DD (95%CI 183 
0.94,2.35) indirect vs. 0.65DD (95%CI 0.40,0.89) direct, P=0.015 (Figure 3b). 184 
 185 
Multiple linear regression analyses were performed on four main outcome 186 
measures: change in FEV1 (% predicted); change in symptom scores; change in 187 
FeNO levels; and AHR doubling dilution differences.  The covariates used as 188 
predictors of these outcomes were: age; gender; and ICS dose ramps (i.e. 0-189 
200µg, 0-800µg and 200-800µg).  ICS dose ramps significantly predicted all 190 
outcomes in keeping with our previous findings: change in FEV1% (p<0.001); 191 
change in symptoms (p=0.012); change in FeNO (p<0.001); and change in AHR 192 
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(p=0.003).  Age was not a significant predictor of any outcome measure.  Gender 193 
was a significant predictor of change in symptom scores (p=0.001), suggesting 194 
male gender correlated with a greater improvement in symptoms, but gender 195 
did not significantly impact on changes in FEV1%, FeNO or AHR. 196 
  197 
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Discussion 198 
 199 
In the present study we have demonstrated that incremental ICS dosing in 200 
persistent asthma leads to small improvements in both pulmonary function and 201 
symptoms, which then reaches a plateau above low doses.  We have also found 202 
that the same ICS dose ramps reveal further room for improvement in both 203 
inflammatory outcomes and AHR, when using higher ICS doses up to 800µg/day 204 
(beclomethasone equivalent). 205 
 206 
The BTS guidelines describe the goal of total (or optimal) asthma control as 207 
comprising no symptoms day or night, normal lung function and no 208 
exacerbations5.  Unfortunately, it has been shown that patients are not good at 209 
recognizing when their asthma is not controlled3.  Furthermore, lingering 210 
underlying inflammation may be present23, and until this is treated, symptoms 211 
may take many months to become completely normal31.  We have shown here 212 
that patients who have only mild pulmonary function and symptom impairment 213 
respond optimally to low doses of ICS for these outcomes.  Pointedly, however, 214 
the 3.3% rise in FEV1 for 0-200µg equated to a mean of 98ml (95%CI 57,140), 215 
which is less than the putative minimal clinically important difference (MCID) of 216 
230ml in asthma32.  Moreover, for symptoms, the geometric mean fold difference 217 
of 0.94 (95%CI 0.90,0.98) in the 200-800µg group equates to around a 6% 218 
improvement.  For the mini-AQLQ, for example, 6% represents a change of 219 
around 0.4, where the MCID is 0.533.  The low dose plateau of symptoms and lung 220 
function have been well documented34-37; for example, Masoli et al. showed no 221 
further improvement in pulmonary function beyond 200µg day of FP37.  Indeed 222 
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Pauwels et al. in the FACET study38 showed a dose response on exacerbations 223 
but not FEV1 comparing 200µg/day vs. 800µg/day of budesonide. Yet we still 224 
largely base our asthma management on these two outcomes, in addition to 225 
reliever use, particularly for mild to moderate persistent asthma; thus limiting 226 
further potentially appropriate ICS escalation. 227 
 228 
We have demonstrated room for further improvement in multiple markers of 229 
inflammation (FeNO, serum ECP and blood Eos) and AHR with higher doses of 230 
ICS, despite the an apparent plateau in symptoms and lung function.  The 231 
presence of ongoing airway inflammation in asthma has been shown to predict 232 
not only future exacerbations21, 39, but also loss of asthma control20 upon 233 
reduction or removal of ICS treatment.  Furthermore, this has been 234 
demonstrated using a variety of inflammatory outcomes including sputum Eos20, 235 
39, blood Eos16, FeNO21 and AHR11, 13.  Moreover, targeted ICS therapy towards 236 
inflammatory outcomes has been shown to reduce the rate of exacerbations10, or 237 
reduce the overall steroid dose required for total control12.  We have found that 238 
while most improvement in FeNO occurs with low dose ICS, there is still a 239 
further dose response to higher ICS doses, particularly in patients who exhibit a 240 
high baseline FeNO≥25ppb.  This dose response has been shown previously, and 241 
indeed when ICS is stopped there is a rebound rise in FeNO once again40, which 242 
alludes to a possible need for persistent over intermittent ICS therapy, or indeed 243 
non-adherence to ICS therapy41.  Indeed, in the FeNOtype study24 (one of the 244 
parent studies of this cohort), significant improvements in asthma control were 245 
seen in the ACQ scores, where patients moved from ‘not well controlled’ to ‘well 246 
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controlled’ with an ACQ <0.75, upon steroid titration that significantly reduced 247 
the patients’ FeNO levels. 248 
 249 
We saw a similar pattern of response to that of inflammatory outcomes with 250 
AHR to a variety of bronchial challenges, both direct and indirect.  Indirect 251 
challenges are more closely related to the inflammatory pathway as they invoke 252 
the inflammatory response in the airway to cause bronchoconstriction22.  This is 253 
perhaps the reason we found a greater magnitude of response for AHR to 254 
indirect than direct challenges, in keeping with previous studies42, 43.  Targeting 255 
ICS therapy using mannitol challenge AHR has been shown to reduce mild 256 
exacerbations over and above standard guideline driven therapy11, in line with 257 
that for sputum eosinophils10.  However, AHR can be driven by other 258 
mechanisms such as airway smooth muscle hyperplasia, and airway closure 259 
itself44, and is therefore an area requiring further study with regards to 260 
personalised asthma treatment45. 261 
 262 
There is therefore a growing body of evidence suggesting that we need to include 263 
inflammatory measurements routinely to best manage patients with asthma.  264 
This is problematic, not least due to the cumbersome nature of inflammatory and 265 
challenge measurements that are difficult to perform in a community setting; 266 
albeit measuring blood eosinophils might be part of the solution16.  Cowan et al. 267 
have suggested using a panel of inflammatory biomarkers to better enable 268 
prediction of ICS responsiveness in asthma46, but delivery of such a test remains 269 
the most difficult hurdle.  Even simply using the asthma control questionnaire24 270 
itself seems to be a good predictor of future risk8. 271 
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 272 
We believe the strengths of this study are in the cross-section of patients with 273 
mild to moderate disease that we commonly see in clinical practice; who 274 
additionally use a variety of ICS moieties.  Furthermore we believe it has been 275 
helpful to study a wide variety of outcome measures, none of which have taken 276 
priority in the study design.  There are significant limitations of this study due to 277 
its post-hoc nature, with relatively low numbers and our ability to only examine 278 
low to moderate, albeit commonly used, doses of small and large particle HFA-279 
ICS.  Additionally, we do not have longer-term outcome data such as any effects 280 
on exacerbation rates.  The findings of this study can, therefore, only generate 281 
hypotheses for larger, longer-term prospective randomised controlled trials.  We 282 
would suggest that they do indeed focus on both phenotyping patients on study 283 
inclusion, as well as examining the impact of combining measures of 284 
inflammation and AHR in addition to asthma control when titrating ICS, rather 285 
than using single outcome measures.   286 
It is likely that when treating any individual patient in real life that the clinician  287 
needs to adopt a multifactorial approach when titrating therapy, using all of the 288 
available information in terms of exacerbations, symptoms, pulmonary function, 289 
reliever use, FENO, blood eosinophils and AHR. This is likely to have the best 290 
predictive value for any given individual in terms of tailoring appropriate ICS 291 
and adjunctive controller therapy to achieve the best long term control. 292 
 293 
In conclusion, we have demonstrated that there may be further room for 294 
improvement in markers of inflammation and AHR, despite a seeming plateau in 295 
the dose response to ICS for both asthma symptoms and pulmonary function, 296 
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with small and large particle ICS HFA-formulations and doses.  This points to a 297 
potential unmet need of uncontrolled underlying airway inflammation in certain 298 
asthmatic patients, which may be a precursor to future loss of asthma control.  299 
We would like to emphasise that fFurther prospective study is however required 300 
to prospectively examine this issue, with particular reference to longer-term 301 
outcomes including exacerbation rates and overall asthma control and how this 302 
relates to inflammatory markers. 303 
 304 
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Study 
Baselines 
All 
n=121 
FP 
(ICS Free) 
n=21 
Bud 
(ICS free) 
n=72 
HFA-BDP 
(200µg BDP) 
n=16 
CIC 
(200µg BDP) 
n=12 
Age (yr) 39.8 
(37.2,42.4) 
36.8 39.6 37.8 48.7 
Sex (M:F) 44:77 6:15 29:43 6:10 3:9 
SPT allergens
§
 3 (2,4) 3 (1,4) 3 (2,3.25) 2.5 (1,4) 1.5 (0,3.25) 
SPT positivity 
(% patients) 
89 81 94 88 63 
FEV1 (% pred) 85.1 
(82.9,87.3) 
88.5 82 90.3 89 
FEF25-75 (% 
Pred) 
65.7 
(61.5,69.8) 
53.5 70.4 60.3 - 
FEV1/FVC ratio 
(%) 
75.2 
(73.7,76.7) 
71.2 75.6 74.6 80.5 
FeNO (ppb)* 37.3 
(32.3,42.6) 
72.4 34.7 29.1 25.4 
(n=10) 
AHR* - 102mg 
(57,183) 
Mann PD15 
0.72 mg/ml 
(0.58,0.90) 
Meth PC20 
1.31mg/ml 
(0.64,2.69) 
Hist PC20 
59mg 
(15,233) 
Mann PD10 
ECP (µg/L)* 
(n=47) 
20.5 
(15.9,26.3) 
18.6 - 22.4 21.9 
Eos (cells/µL) 
(n=37) 
330 
(280,390) 
370 - 290 - 
Symptom 
Score 
- 5.8 
(5.4,6.2) 
0.96
¶
 
(0.79,1.12) 
6.2 
(5.9,6.5) 
6.1 
(5.6,6.5) 
Screening ICS 
(BDP, µg/day) 
420 
(361,479) 
440 414 406 436 
 1 
Table 1.  Baselines post run-in at the given beclomethasone dipropionate (BDP) equivalent 2 
doses for: large-particle hydrofluoroalkane (HFA)-fluticasone propionate (FP), large-particle 3 
HFA-budesonide (Bud), small-particle HFA-beclomethasone (HFA-BDP), and small-particle HFA-4 
ciclesonide (CIC).  SPT = Skin Prick Test to common allergens.  Overall means (95%CI), leftmost 5 
column.  Arithmetic means (95%CI), unless stated.  *Geometric mean (95%CI).  §Median 6 
number of allergens (interquartile range).  Symptom scores are the symptom component of the 7 
mini-AQLQ, except Bud. ¶Total Symptom Score: 0-no symptoms; 1-mild; 2-moderate; and 3-8 
severe. 9 
 10 
Table 1
1 
 
ICS BDP (µg/day) ICS Free 
(a) 
200ug 
(b) 
800ug 
(c) 
P-value 
(ANOVA) 
 
Pulmonary Function 
FEV1 (% pred) 83.4 
(81.0,85.9) 
n=93 
87.6§ 
(85.4,89.9) 
n=121 
87.9§ 
(86.0,89.9) 
n=121 
0.01 
FEF25-75 (% pred) 66.6 
(62.0,71.2) 
n=93 
69.6 
(65.7,73.5) 
n=109 
70.0 
(66.1,73.8) 
n=109 
0.47 
 
Inflammatory Outcomes 
FeNO (ppb)* 40.4 
(34.7,46.9) 
n=93 
26.8♯ 
(23.4,30.2) 
n=115 
20.8♯¶ 
(18.8,23.1) 
n=115 
<0.0001 
ECP (µg/L)* 18.7 
(12.1,28.8) 
n=21 
20.2 
(15.3,26.5) 
n=47 
13.2 (9.9,17.4) 
n=47 
0.08 
Eos (cells/µL) 370 (280,450) 
n=21 
300 (240,350) 
n=38 
250§ (200,300) 
n=38 
0.04 
 1 
Table 2.  Pulmonary function and inflammatory outcomes.  Data presented as arithmetic means 2 
(95% confidence intervals) unless otherwise stated. *Geometric mean (95% CI).  §P<0.05 vs. (a).  3 
¶ P=0.01 vs. (b). ♯P<0.001 vs. (a). 4 
 5 
 6 
Table 2
1 
 
Figure Legends 1 
Figure 1. Dose Responses for FEV1 and Symptom Scores.  (a) mean percentage changes 2 
(95%CI error bars) for FEV1 as %predicted.  (b) change in symptom scores as geometric 3 
mean fold differences (GMFDs, 95% CI error bars); scores <1 indicate improvement.  4 
Asterisk denotes significant within-group change, P<0.05.  Remaining P-values compare 5 
responses between groups. 6 
 7 
Figure 2.  Dose-responses for inflammatory outcomes.  Within-group changes (GMFDs, 8 
95%CI) unless stated; scores <1 represent a reduction.  (a) FeNO.  (b) FeNO comparing 9 
baseline FeNO≥25ppb (squares) vs. FeNO<25ppb (circles).  (c) serum ECP.  (d) blood 10 
eosinophils, arithmetic mean (95%CI).  Asterisk denotes significant within-group 11 
difference, P<0.05.  Remaining P-values indicate significant between group differences; or 12 
significant differences between baseline FeNO groups within each ramp (b), P<0.05. 13 
 14 
Figure 3.  Dose-responses in airway hyper-responsiveness (AHR).  Within-group changes 15 
expressed as doubling dilution differences (DDD).  Scores >0 indicate improvement. (a) 16 
combined bronchial challenges: 0-200, n=93; 0-800, n=93; 200-800, n=120. (b) direct (circles) 17 
vs. indirect (squares) challenges: direct 0-200, n=72; direct 0-800, n=72; direct 200-800, n=88; 18 
indirect 0-200, n=21; indirect 0-800, n=21; indirect 200-800, n=32.  Asterisk denotes significant 19 
within group change, P<0.05.  Remaining P-values indicate significant between group 20 
differences (a), or significant differences between challenge groups within each ramp (b), 21 
P<0.05. 22 
 23 
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